Result of General Meeting Completion of Fundraise
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE EU REGULATION 596/2014 AS IT FORMS PART OF THE UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“MAR”). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
(“BiVictriX” or the “Company”)
Result of General Meeting
Completion of Fundraise
Total Voting Rights
Alderley Park, 8 August 2023 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a differentiated approach to develop next-generation cancer therapies with substantially improved cancer cell selectivity and anti-cancer activity, announces that at the Company’s General Meeting held today at 11:00 a.m. at the Company’s registered office, Mereside Alderly Park, Alderly Edge, Manchester SK10 4TG, all resolutions were duly passed. Further details of each of the resolutions are set out in the Circular and Notice of Meeting, which was sent to shareholders on 20 July 2023 (the “Circular”).
Details of proxy votes received are summarised below:
|Resolution||Votes For||Votes Against||Discretionary Votes||Withheld|
|In accordance with section 551 of the Companies Act 2006, the directors of the Company in addition to all previous authorities granted to the Directors, be generally and unconditionally authorised to exercise all the powers of the Company to allot shares in the Company, and grant rights to subscribe for or convert any securities into shares in the Company, up to an aggregate nominal amount of £164,108.87 (within the meaning of sections 551(3) and (6) of the said Act), in connection with the Fundraise detailed in the Circular.
|In accordance with section 570 of the Act, the Directors be generally empowered to allot equity securities (as defined in section 560(1) of the Act) which are the subject of the authority conferred by resolution 1 as if section 561 of the Act did not apply to such allotment, provided that this power shall be limited to the allotment of equity securities up to an aggregate nominal amount of £164,108.87, in connection with the Fundraise detailed in the Circular.
Completion of Fundraise
The Resolutions were necessary to implement the Fundraise to raise a total of £2.1 million (before expenses), as announced by the Company on 19 July 2023.
Following the passing of the Resolutions, the Company has allotted (subject only to Admission) the Placing Shares and the Subscription Shares with new and existing investors (the “New Ordinary Shares”). The New Ordinary Shares will rank pari passu with the Company’s Existing Ordinary Shares.
Admission to AIM and Total Voting Rights
Application has been made for the Admission of 16,410,887 New Ordinary Shares. It is expected that Admission will take place and that trading in the New Ordinary Shares will commence, at 8.00 a.m. on 10 August 2023.
Following Admission, the Company’s issued and fully paid share capital will consist of 82,526,088 Ordinary Shares. The Company has no Ordinary Shares in treasury. As such, the total number of voting rights in the Company will be 82,526,088 Ordinary Shares. Following Admission, this number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.
This announcement should be read in conjunction with the full text of the Circular sent to shareholders on 20 July 2023 in connection with the Fundraise. Capitalised terms used but not otherwise defined in this announcement bear the meanings ascribed to them in the Circular.
| For more information, please contact:
About BiVictriX Therapeutics plc
BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX’s first-in-class Bi-Cygni® Antibody Drug Conjugates (ADCs) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.